Get the app!
Back to Trades
Filing Date
May 8, 2026
1 transactions

Trade Summary

On Apr 30, 2026, Artal Participations S.a r.l., Insider, reported $0 of LEXICON PHARMACEUTICALS, INC. (LXRX) across 1 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
LXRX
CIK
0001062822

Insider Information

Role
Insider

Filing Details

Filing Date
May 8, 2026
Transaction Date
Apr 30, 2026
Accession Number
0001193125-26-215297
Form Type
4

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Apr 30, 2026Common Stock20,421,735Exercise

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Apr 30, 2026LXRX derivative408,434.7Grant/Award
Apr 30, 2026LXRX derivative408,434.7Exercise

Want live alerts when Artal Participations S.a r.l. trades again?

Download Insider Trades to track LXRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock.
  2. (F2)These securities are directly held by Artal Participations S.a r.l.
  3. (F3)The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
  4. (F4)Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.